State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus

Julie Rodriguez; Zahra Hassani; Carolina Alves Costa Silva; Human Microbiome Action consortium; Fay Betsou; Federica Carraturo; Alessio Fasano; Mads Israelsen; Anandhi Iyappan; Aleksander Krag; Amira Metwaly; Robert Schierwagen; Jonel Trebicka; Hub Zwart; Joel Doré; Magali Cordaillat-Simmons; Celine Druart; Yolanda Godoy; Peer Bork; Nassos Typas; Dienty Hendrina Maria Johanna Hazenbrink; Laurence Zitvogel; Lisa Derosa; Hervé Blottière; Aicha Kriaa; Emmanuelle Maguin; Moez Rhimi; Patrick Veiga; Nicolas Pons; Pierre Louis Prost; Alexander Jarde; Isabelle Boutron; Philippe Ravaud; Ida Falk Villesen; Dirk Haller; Paul Ross; Paul O'Toole; Aonghus Lavelle; Marcus Claesson; Raphaela Joos; Colin Hill; Andrey Shkoporov; Saba Loftus; Katy Boucher; Manimozhayan Arumugam; Arjun Sarathi; Vitalina Morozova; Nicola Segata; Francesco Asnicar; Federica Pinto

doi:10.1016/j.lanmic.2024.07.011

State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus

Julie Rodriguez, Zahra Hassani, Carolina Alves Costa Silva, Human Microbiome Action consortium, Fay Betsou, Federica Carraturo, Alessio Fasano, Mads Israelsen, Anandhi Iyappan, Aleksander Krag, Amira Metwaly, Robert Schierwagen, Jonel Trebicka, Hub Zwart, Joel Doré, Magali Cordaillat-Simmons, Celine Druart^*, Yolanda Godoy, Peer Bork, Nassos TypasDienty Hendrina Maria Johanna Hazenbrink, Laurence Zitvogel, Lisa Derosa, Hervé Blottière, Aicha Kriaa, Emmanuelle Maguin, Moez Rhimi, Patrick Veiga, Nicolas Pons, Pierre Louis Prost, Alexander Jarde, Isabelle Boutron, Philippe Ravaud, Ida Falk Villesen, Dirk Haller, Paul Ross, Paul O'Toole, Aonghus Lavelle, Marcus Claesson, Raphaela Joos, Colin Hill, Andrey Shkoporov, Saba Loftus, Katy Boucher, Manimozhayan Arumugam, Arjun Sarathi, Vitalina Morozova, Nicola Segata, Francesco Asnicar, Federica Pinto

^*Corresponding author for this work

WP ESPhil

Research output: Contribution to journal › Review article › Academic › peer-review

7 Citations (Scopus)

6 Downloads (Pure)

Abstract

Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human Microbiome Action consortium initiated a Delphi survey to establish a consensus on the needs, challenges, and limitations in developing qualified microbiome-based biomarkers. The questionnaire was developed by a scientific committee via literature review and expert interviews. To ensure broad applicability of the results, 307 experts were invited to participate; 114 of them responded to the first round of the survey, 93 of whom completed the second and final round as well. The survey highlighted the experts’ confidence in the potential of microbiome-based biomarkers for several indications or pathologies. The paucity of validated analytical methods appears to be the principal factor hindering the qualification of these biomarkers. The survey also showed that clinical implementation of these biomarkers would only be possible if kitted and validated molecular assays with simple interpretation are developed. This initiative serves as a foundation for designing and implementing public-private collaborative projects to overcome the challenges and promote clinical application of microbiome-based biomarkers.

Original language	English
Article number	100948
Journal	The Lancet Microbe
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/j.lanmic.2024.07.011
Publication status	E-pub ahead of print - 5 Sept 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lanmic.2024.07.011Licence: CC BY-NC-ND

1-s2.0-S2666524724002015-mainProof, 346 KBLicence: CC BY-NC-ND

Cite this

Rodriguez, J., Hassani, Z., Alves Costa Silva, C., Human Microbiome Action consortium, Betsou, F., Carraturo, F., Fasano, A., Israelsen, M., Iyappan, A., Krag, A., Metwaly, A., Schierwagen, R., Trebicka, J., Zwart, H., Doré, J., Cordaillat-Simmons, M., Druart, C., Godoy, Y., Bork, P., ... Pinto, F. (2024). State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus. The Lancet Microbe, 6(2), Article 100948. Advance online publication. https://doi.org/10.1016/j.lanmic.2024.07.011

@article{d7f206f4943140a3bf83682eaaaefaf7,

title = "State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus",

abstract = "Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human Microbiome Action consortium initiated a Delphi survey to establish a consensus on the needs, challenges, and limitations in developing qualified microbiome-based biomarkers. The questionnaire was developed by a scientific committee via literature review and expert interviews. To ensure broad applicability of the results, 307 experts were invited to participate; 114 of them responded to the first round of the survey, 93 of whom completed the second and final round as well. The survey highlighted the experts{\textquoteright} confidence in the potential of microbiome-based biomarkers for several indications or pathologies. The paucity of validated analytical methods appears to be the principal factor hindering the qualification of these biomarkers. The survey also showed that clinical implementation of these biomarkers would only be possible if kitted and validated molecular assays with simple interpretation are developed. This initiative serves as a foundation for designing and implementing public-private collaborative projects to overcome the challenges and promote clinical application of microbiome-based biomarkers.",

author = "Julie Rodriguez and Zahra Hassani and {Alves Costa Silva}, Carolina and {Human Microbiome Action consortium} and Fay Betsou and Federica Carraturo and Alessio Fasano and Mads Israelsen and Anandhi Iyappan and Aleksander Krag and Amira Metwaly and Robert Schierwagen and Jonel Trebicka and Hub Zwart and Joel Dor{\'e} and Magali Cordaillat-Simmons and Celine Druart and Yolanda Godoy and Peer Bork and Nassos Typas and Hazenbrink, {Dienty Hendrina Maria Johanna} and Laurence Zitvogel and Lisa Derosa and Herv{\'e} Blotti{\`e}re and Aicha Kriaa and Emmanuelle Maguin and Moez Rhimi and Patrick Veiga and Nicolas Pons and Prost, {Pierre Louis} and Alexander Jarde and Isabelle Boutron and Philippe Ravaud and {Falk Villesen}, Ida and Dirk Haller and Paul Ross and Paul O'Toole and Aonghus Lavelle and Marcus Claesson and Raphaela Joos and Colin Hill and Andrey Shkoporov and Saba Loftus and Katy Boucher and Manimozhayan Arumugam and Arjun Sarathi and Vitalina Morozova and Nicola Segata and Francesco Asnicar and Federica Pinto",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = sep,

day = "5",

doi = "10.1016/j.lanmic.2024.07.011",

language = "English",

volume = "6",

journal = "The Lancet Microbe",

issn = "2666-5247",

publisher = "Elsevier Ltd.",

number = "2",

}

Rodriguez, J, Hassani, Z, Alves Costa Silva, C, Human Microbiome Action consortium, Betsou, F, Carraturo, F, Fasano, A, Israelsen, M, Iyappan, A, Krag, A, Metwaly, A, Schierwagen, R, Trebicka, J, Zwart, H, Doré, J, Cordaillat-Simmons, M, Druart, C, Godoy, Y, Bork, P, Typas, N, Hazenbrink, DHMJ, Zitvogel, L, Derosa, L, Blottière, H, Kriaa, A, Maguin, E, Rhimi, M, Veiga, P, Pons, N, Prost, PL, Jarde, A, Boutron, I, Ravaud, P, Falk Villesen, I, Haller, D, Ross, P, O'Toole, P, Lavelle, A, Claesson, M, Joos, R, Hill, C, Shkoporov, A, Loftus, S, Boucher, K, Arumugam, M, Sarathi, A, Morozova, V, Segata, N, Asnicar, F & Pinto, F 2024, 'State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus', The Lancet Microbe, vol. 6, no. 2, 100948. https://doi.org/10.1016/j.lanmic.2024.07.011

TY - JOUR

T1 - State of the art and the future of microbiome-based biomarkers

T2 - a multidisciplinary Delphi consensus

AU - Rodriguez, Julie

AU - Hassani, Zahra

AU - Alves Costa Silva, Carolina

AU - Human Microbiome Action consortium

AU - Betsou, Fay

AU - Carraturo, Federica

AU - Fasano, Alessio

AU - Israelsen, Mads

AU - Iyappan, Anandhi

AU - Krag, Aleksander

AU - Metwaly, Amira

AU - Schierwagen, Robert

AU - Trebicka, Jonel

AU - Zwart, Hub

AU - Doré, Joel

AU - Cordaillat-Simmons, Magali

AU - Druart, Celine

AU - Godoy, Yolanda

AU - Bork, Peer

AU - Typas, Nassos

AU - Hazenbrink, Dienty Hendrina Maria Johanna

AU - Zitvogel, Laurence

AU - Derosa, Lisa

AU - Blottière, Hervé

AU - Kriaa, Aicha

AU - Maguin, Emmanuelle

AU - Rhimi, Moez

AU - Veiga, Patrick

AU - Pons, Nicolas

AU - Prost, Pierre Louis

AU - Jarde, Alexander

AU - Boutron, Isabelle

AU - Ravaud, Philippe

AU - Falk Villesen, Ida

AU - Haller, Dirk

AU - Ross, Paul

AU - O'Toole, Paul

AU - Lavelle, Aonghus

AU - Claesson, Marcus

AU - Joos, Raphaela

AU - Hill, Colin

AU - Shkoporov, Andrey

AU - Loftus, Saba

AU - Boucher, Katy

AU - Arumugam, Manimozhayan

AU - Sarathi, Arjun

AU - Morozova, Vitalina

AU - Segata, Nicola

AU - Asnicar, Francesco

AU - Pinto, Federica

PY - 2024/9/5

Y1 - 2024/9/5

N2 - Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human Microbiome Action consortium initiated a Delphi survey to establish a consensus on the needs, challenges, and limitations in developing qualified microbiome-based biomarkers. The questionnaire was developed by a scientific committee via literature review and expert interviews. To ensure broad applicability of the results, 307 experts were invited to participate; 114 of them responded to the first round of the survey, 93 of whom completed the second and final round as well. The survey highlighted the experts’ confidence in the potential of microbiome-based biomarkers for several indications or pathologies. The paucity of validated analytical methods appears to be the principal factor hindering the qualification of these biomarkers. The survey also showed that clinical implementation of these biomarkers would only be possible if kitted and validated molecular assays with simple interpretation are developed. This initiative serves as a foundation for designing and implementing public-private collaborative projects to overcome the challenges and promote clinical application of microbiome-based biomarkers.

AB - Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human Microbiome Action consortium initiated a Delphi survey to establish a consensus on the needs, challenges, and limitations in developing qualified microbiome-based biomarkers. The questionnaire was developed by a scientific committee via literature review and expert interviews. To ensure broad applicability of the results, 307 experts were invited to participate; 114 of them responded to the first round of the survey, 93 of whom completed the second and final round as well. The survey highlighted the experts’ confidence in the potential of microbiome-based biomarkers for several indications or pathologies. The paucity of validated analytical methods appears to be the principal factor hindering the qualification of these biomarkers. The survey also showed that clinical implementation of these biomarkers would only be possible if kitted and validated molecular assays with simple interpretation are developed. This initiative serves as a foundation for designing and implementing public-private collaborative projects to overcome the challenges and promote clinical application of microbiome-based biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85203047983&partnerID=8YFLogxK

U2 - 10.1016/j.lanmic.2024.07.011

DO - 10.1016/j.lanmic.2024.07.011

M3 - Review article

C2 - 39243797

AN - SCOPUS:85203047983

SN - 2666-5247

VL - 6

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 2

M1 - 100948

ER -

State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this